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Outpatient vancomycin use and vancomycin-resistant entero- Many nephrologists frequently use vancomycin for the
coccal colonization in maintenance dialysis patients. empiric treatment of dialysis-associated infections [1–3],
Background. Although outpatient vancomycin is widely used despite recommendations to the contrary [4, 5]. Vanco-as empiric therapy for dialysis-associated infections, its rela-
mycin has the advantage of being highly effective againsttionship with vancomycin-resistant enterococcal (VRE) coloni-
gram-positive organisms, including those resistant tozation is not established.
Methods. During a two-year prospective cohort study, rec- methicillin, and of having an extended duration of action
tal swabs obtained from patients at the start and finish of the in end-stage renal disease. Unfortunately, its increased
study period and during interim hospitalizations were cultured use has been associated with a dramatic increase in hospi-for VRE.
tal-acquired infections with vancomycin-resistant enter-Results. Ten of 124 patients initially grew VRE. Twenty-four
ococci (VRE). This resistance is usually genetically medi-of the remaining patients had no follow-up cultures because of
patient death (62%), transfer to another dialysis facility (17%), ated and is potentially transferable between bacterial
patient’s refusal (7%), and transplantation (4%), and were species [6–8]. Moreover, the danger exists that resistance
thus excluded. The remaining patients (N 5 90) had a median
may develop in more virulent organisms such as Staphy-age of 54.3 years and were 92% African American and 50%
lococcus aureus, as has been described in several casemale. Fifty-eight percent were treated by hemodialysis. They
received 403 g of intravenous vancomycin over 157.2 patient- reports [9–14]. Much of the existing literature regarding
years of follow-up, 73% as outpatients. Sixteen of 90 patients VRE infection relates to in-hospital practice and thus may
(17.8%) became colonized with VRE, an incidence rate of one not apply to the outpatient dialysis setting. In addition,
case per 9.8 patient-years of follow-up. None of the 29 patients
several studies have failed to demonstrate an increase inwho did not receive vancomycin developed VRE compared
the prevalence of VRE among dialysis patients, despitewith 26% of those treated with vancomycin (P 5 0.001). The
odds ratio (95% CI) for the association of outpatient vancomy- the widespread use of vancomycin [3, 15–18]. We con-
cin (g per year) with VRE colonization was 1.23 (1.05, 1.44, P 5 ducted the following study to define the incidence of
0.008). The association remained significant following adjust- VRE colonization in the dialysis population and to exam-
ment in separate logistic regression analyses for relevant demo-
ine specifically the association between outpatient van-graphic, clinical, antimicrobial (inpatient vancomycin, oral or
comycin use and the development of VRE colonization.intravenous cephalosprins, aminoglycosides, quinalones, or anti-
anaerobics), and hospitalization exposures. The unadjusted rel-
ative risk of death in patients growing VRE was significantly
METHODShigher than in those not colonized with VRE (P 5 0.005).
Conclusions. VRE colonization is a relatively common and Study design
underrecognized problem among chronic dialysis patients. It
In December of 1996, we conducted a cross-sectionalis strongly and independently associated with the outpatient use
of vancomycin, which should be avoided whenever possible. prevalence study of VRE colonization in our outpatient
dialysis center, a freestanding unit located in East Balti-
more (MD, USA). Using a standardized protocol, peri-
1 Drs. Atta and Eustace contributed equally to this study. rectal swabs (culturette; Becton Dickinson Microbiology
system, Cockeysville, MD, USA) were obtained from allKey words: end-stage renal disease, infection, chronic dialysis, dialysis-
related infection, gram-positive organisms, bacteria. consenting patients and were cultured for VRE. Patients
whose initial cultures did not grow VRE were enteredReceived for publication May 5, 2000
into a cohort study and followed for up to a maximumand in revised form August 31, 2000
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cultured for VRE colonization, as part of routine hospital time of study entry (December 1996) until the time of
their first positive VRE rectal culture or until the lastpractice. Standard infection control measures in the dial-
ysis unit included the use of universal precautions and recorded negative culture either at the end of the study
or prior to the subject exiting the cohort. Patients exitedthe cleaning of all dialysis equipment and the dialysis
chair between uses with 2% bleach solution. No specific the cohort prior to study’s termination due to trans-
plantation, transfer to another dialysis unit, or patientprocedures were in place for dialyzing patients with a
history of VRE infection or colonization. In-hospital death. Patients who had no repeat rectal culture during
the course of the study and whose follow-up VRE statusmanagement included the use of gowns and gloves and
the isolation or cohorting of known VRE colonized or was thus unknown were, by necessity, excluded from the
primary analysis. Patients who had a positive VRE rectalinfected patients. These infection control measures were
unchanged over the period of the study. At the end of the swab obtained within 48 hours of hospitalization were
assumed to have had VRE colonization prior to hospital-study period (December 1998), we conducted a second
cross-sectional prevalence study of VRE rectal coloniza- ization and did not have this last hospitalization counted
among their exposure data. As the duration of follow-tion in all surviving cohort members.
up was different for different subjects, exposure data
Outcome ascertainment were expressed in terms of a subject’s average exposure
per year.Patients were defined as being colonized with VRE
only if a cultured rectal swab grew VRE without clinical
Primary analysisinfection. Rectal swabs were cultured using an identical
technique throughout the study period. In brief, speci- In the primary analysis, the effects of vancomycin ad-
ministered in the chronic dialysis unit were studied sepa-mens were plated on agar appropriate for each body site
and on selective trypticase soy agar media containing rately from that administered within the hospital. The
5% sheep’s blood, 10 mg/mL vancomycin, and 8 mg/mL influence of topical antimicrobial preparations and of pro-
gentamicin. Colonies consistent with enterococcus, which phylactic use of cotrimoxazole among HIV patients—on
hydrolyze PYR and were gram positive, were speciated which we had incomplete data—was not examined. A
using motility, pigment production, and 10% lactose subgroup analysis was, however, performed excluding
tests. Final speciation occurred according the scheme of HIV seropositive patients.
Facklam and Collins [19]. Vancomycin susceptibility was
Statistical methodstested using agar dilution technique and concentrations
of vancomycin of 1, 2, 4, 16, and 64 mg/mL. If the organ- Outlying values for the distribution of each variable
ism had a minimal inhibitory concentration (MIC) of were identified using boxplots, and their validity was
greater than 16 but less than 64, the E test was used to checked against the original clinical record. The VRE-
confirm according to the National Committee for Clini- positive and -negative groups were compared using the
cal Laboratory Standards [20]. Mann-Whitney U test for continuous and the Fisher’s
exact test for categorical data. The association of outpa-
Exposure assessment tient vancomycin use with the development of VRE was
Baseline demographic information and clinical charac- examined using unconditional logistic regression. The
teristics of the participating subjects were abstracted influence of individual potential confounders was exam-
from the patients’ medical records. The dose of vancomy- ined, one at a time, in separate logistic regression analy-
cin, as well as any additional antibiotics, administered ses. Because of the limited available sample size, more
or prescribed in the dialysis unit was obtained from dial- extensive regression modeling was not attempted. Pa-
ysis unit records. These antibiotics were prescribed ac- tient survival was examined using the Kaplan–Meier
cording to the discretion of the attending physician and method and compared using the log rank test. Patients
without use of standing orders. In-patient antibiotic use were censored at the time of transplantation or at loss
was obtained from the hospital’s pharmacy record, and to follow-up. For all analyses, a type I error rate of 0.05
details regarding the in-patient hospital stay and inten- was used. Statistical analysis was performed using SPSS
sive care unit admissions were obtained from the Johns software, version 7.5 (Chicago, IL, USA).
Hopkins Hospital case-mix database, a database that
records the duration and location of patients’ stay in the
RESULTShospital. Information on orally prescribed antibiotics was
One hundred twenty-four of the 147 patients (84.4%)checked by cross-referencing data from the hospital out-
attending our dialysis unit in December 1996 agreedpatient pharmacy. As this pharmacy delivers medicine
to participate in the study. Seventy-four patients weredirectly to the dialysis unit, it is widely, although not
treated with hemodialysis and the remaining 50 withexclusively, used by our dialysis patients.
Exposure data were obtained for all patients from the peritoneal dialysis. Ten of the 124 (8%) patients were
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Table 1. Comparison of baseline demographics and clinical two groups’ antibiotics and hospitalization exposure are
characteristics by follow-up vancomycin resistant enterococcal
compared in Table 2. Of the 29 patients who did not(VRE) culture status
receive vancomycin, none became colonized with VRE,
Colonized Non-colonized whereas 26% of patients who received at least one dosewith VRE with VRE P
of vancomycin developed VRE during the course of the
Number of subjects 16 74
study (P 5 0.001). The median outpatient vancomycinAge years 60.9 (33.7–77.5) 49.1 (23.2–87.2) NS
Gender exposure was 3.3 g per year higher among the VRE-
Male, N % 6 (37.5) 39 (52.7) NS colonized group than among those not colonized withFemale, N % 10 (62.5) 35 (47.3)
VRE (P 5 0.002). The VRE-colonized group also hadRace
Black, N % 13 (81.3) 70 (94.6) 0.10 significantly greater exposures to inpatient vancomycin,
White, N % 3 (18.8) 4 (5.4) aminoglycosides, anaerobic antimicrobial agents, hospi-Diabetes mellitus N % 11 (68.8) 36 (48.6) NS
tal admissions, duration of in-hospital stay, and intensiveHIV seropositive N % 1 (6.3) 7 (9.5) NS
Hemodialysis N % 10 (62.5) 42 (56.8) NS care unit admissions.
Peritoneal dialysis N % 6 (37.5) 32 (43.2) Using logistic regression, outpatient vancomycin (g perDuration of ESRD years 2.1 (0.3–5.7) 2.2 (0.1–24.7) NS
year) was significantly associated with the development
Group summary data are expressed as median (range) or number (%) of
subjects as appropriate. NS is not significant. of VRE with an odds ratio (95% CI) of 1.23 (1.05, 1.44).
This association remained significant following adjust-
ment in separate analyses for the main potential con-
founders, as shown in Table 3. This odds ratio for thecolonized with VRE when initially cultured (1996) and
are not entered into the follow-up cohort. This result association between outpatient vancomycin use and VRE
was perceived as being similar to that reported by others colonization was reduced in only three of these analyses,
[3, 15–18] and did not lead to any formal change in as compared with the unadjusted odds ratio (1.23). In
the use of vancomycin in our unit. Twenty-four of the each case, however, outpatient vancomycin continued to
remaining patients initially without VRE were not ana- exert a significant and independent effect. Adjustment
lyzable, as they had no subsequent VRE culture, and thus for the other potential confounders resulted in either
their follow-up VRE status was unknown. One patient no effect or a slight increase in this odds ratio. When
underwent renal transplantation. Four transferred to an- outpatient vancomycin was simultaneously adjusted for
other dialysis unit, and 15 died before the VRE screen average duration of hospital stay and either inpatient
at the end of the study. An additional four patients re- vancomycin dose or number of hospitalizations, the asso-
mained within the cohort but declined to undergo repeat
ciation between outpatient vancomycin (g per year) andVRE screening at the end of follow-up. In comparison
VRE colonization continued to be significant, with anto the analyzable group, these 24 patients were older (P 5
odds ratio of 1.29 (1.07, 1.57, P 5 0.007) and 1.22 (1.03,0.03) and were more likely to be Caucasian (P 5 0.003).
1.45, P 5 0.02), respectively. More extensive regression
VRE incidence rate modeling was not undertaken because of the small num-
ber of available cases (N 5 16). Repeat analyses usingThe 90 analyzable patients contributed a total of 157.2
combined inpatient and outpatient vancomycin dose andyears of follow-up, with a mean duration of follow-up
a subgroup analysis excluding HIV seropositive subjectsper subject of 1.75 years. Sixteen incident cases of VRE
revealed similar significant results as that of the primaryrectal colonization were detected over the course of the
study, an incidence rate of 1 case per 9.83 patient years analysis (data not shown).
of follow-up.
Clinical VRE infectionOf the 90 patients, only 70 patients underwent repeat
VRE screening at the end of the study, of whom 6 pa- Over the course of follow-up, 6 out of 16 (37.5%)
tients (8.6%) grew VRE. Two of these patients had their VRE colonized patients developed an overt infection
VRE status established previously during prior hospital- related to VRE, including one surgical site infection, one
izations; however, the VRE colonization status of the urinary tract infection, one episode of peritonitis, and
remaining four subjects had been unknown to the dialysis three cases of VRE bacteremia, confirmed in at least
staff.
two blood culture bottles. Ten of the 90 patients (11.0%),
whose follow-up VRE status was known died over theDeterminants of VRE colonization
course of the study. Six deaths occurred among the 74The 90 patients received a total of 403 g of intravenous
patients (8.0%) who did not grow VRE, 4 among thevancomycin, 73% of which was administered in the out-
16 patients (25%) who grew VRE, including 2 of the 3patient dialysis unit. There was no significant difference
bacteremic patients. Survival in the VRE colonizedin the baseline demographic characteristics, the propor-
group was significantly worse than for the noncolonizedtion of patients with HIV infection, or diabetes between
patients who grew and did not grow VRE (Table 1). The group (P 5 0.005; Fig. 1).
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Table 2. Comparison of number of subjects (%) exposed and median (range) yearly level of exposure for VRE-colonized and VRE
non-colonized groups
Colonized with VRE (N 5 16) Non-colonized with VRE (N 5 74)
N (%) Median (range) N (%) Median (range)
exposed in those exposed exposed in those exposed P a
Average total vancomycin g/year 16 (100) 6.0 (1.0, 30.0) 45 (60.8) 2.0 (0.3, 36.5) ,0.001
Average inpatient vancomycin g/year 14 (88) 3.2 (0.6, 8.3) 26 (35) 0.7 (0.3, 36.5) ,0.001
Average outpatient vancomycin g/year 13 (81) 3.6 (1.0, 30.0) 35 (47) 2.0 (0.5, 13.1) 0.002
Average total aminoglycoside mg/year 15 (93.8) 942 (122, 3150) 48 (64.9) 208 (20, 7326) ,0.001
Average 3rd generation cephalosporins g/year 7 (43.8) 5.2 (1.1, 47.7) 19 (25.7) 2.8 (0.5, 144.0) NS
Average 1st & 2nd generation cephalosporins g/year 1 (6) 7.6 14 (19) 6.8 (1.7, 27.5) NS
Average total ciprofloxacin g/year 5 (31.3) 5.6 (0.2, 191.0) 20 (27.0) 6.9 (0.7, 11.6) NS
Average total anti-anaerobics g/year 8 (50) 5.3 (1.85, 25.2) 18 (24.3) 1.2 (0.3, 233.3) 0.01
Average number of hospitalizations per year 16 (100) 3.2 (0.6, 14.4) 59 (80) 1.5 (0.5, 17.4) ,0.001
Average duration of hospital stay per year 16 (100) 19.7 (2.7, 59.6) 59 (80) 9.0 (0.5, 46.9) ,0.001
Average number of ICU admissions per year 16 (100) 1.5 (0.5, 17.4) 59 (79.7) 3.2 (0.60, 14.4) 0.01
NS is not significant.
a For comparison of median yearly exposure between all subjects in both groups
Table 3. Odds ratio (95% CI) for the association of outpatient vancomycin use with VRE-colonization, both unadjusted and adjusted in
separate analyses for the major demographic, clinical, antimicrobial and hospitalization exposures
Odds ratio 22 Log likelihood
(95% CI) P valuea for specified model
Unadjusted 1.23 (1.05, 1.44) 0.008 72.54
Demographic and clinical data
Adjusted for age 1.24 (1.05, 1.45) 0.001 68.78
Adjusted for gender 1.27 (1.07, 1.50) 0.001 70.21
Adjusted for race 1.23 (1.05, 1.44) 0.01 71.37
Adjusted for dialysis modality 1.26 (1.07, 1.49) 0.006 70.62
Adjusted for duration of dialysis 1.23 (1.05, 1.43) 0.009 72.51
Adjusted for diabetes mellitus 1.27 (1.06, 1.50) 0.007 69.26
Adjusted for HIV seropositive 1.23 (1.05, 1.44) 0.009 72.51
Antimicrobial data
Adjusted for average in-patient vancomycin g/year 1.21 (1.04, 1.40) 0.013 70.63
Adjusted for average total aminoglycoside mg/year 1.23 (1.05, 1.44) 0.008 71.6
Adjusted for average 3rd generation cephalosporins g/year 1.23 (1.05, 1.44) 0.008 72.47
Adjusted for average 1st & 2nd generation cephalosporins g/year
Adjusted for average ciprofloxacin g/year 1.23 (1.05, 1.43) 0.008 72.35
Adjusted for average antianaerobics g/year 1.23 (1.05, 1.44) 0.008 72.47
Hospitalization data
Adjusted for average duration of hospital stay days per year 1.21 (1.03, 1.41) 0.02 56.7
Adjusted for average number of hospitalizations per year 1.19 (1.03, 1.38) 0.02 69.2
Adjusted for average number of ICU admissions per year 1.26 (1.07, 1.48) 0.007 67.38
ICU is intensive care unit.
a P value for association of out-patient vancomycin use with VRE colonization post-adjustment for specified variable
DISCUSSION In the 11 years since it was first described, VRE has
become a global health concern [21]. The excretion ofOur study is the first, to our knowledge, to define the
VRE has been shown to dramatically increase followingincidence of detectable VRE colonization in a cohort of
exposure to vancomycin [22]. The unrestricted and rapidoutpatient dialysis subjects. In both our 1996 and 1998
increase in the use of vancomycin over the last two de-prevalence studies, we found comparable prevalence ra-
cades has been implicated in the rapid spread of VRE.tios (8 and 8.5%) to that described in other cross-sectional
In one center, the amount of vancomycin prescribed in-studies. However, the calculated incidence ratio per year
creased 20-fold in the period between 1981 and 1991 [23].was higher than either of these two point prevalence
The Centers for Disease Control and Prevention hasestimates. In keeping with this observation, we detected
specifically advised that vancomycin should not be useda decreased survival in the VRE colonized as compared
for prophylactic or empiric therapy or for reasons ofwith the noncolonized subjects; however, in this data set
dosing convenience when alternative treatment optionswe cannot determine whether this association is in any
way causal in nature. are available. In response, the Ad Hoc Committee on
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tion-control practices both within the dialysis unit and
hospital and the degree of patient comorbidity, also un-
doubtedly influence the background incidence of VRE,
although an analysis of these influences was beyond the
scope of our study. The potential influence of dialysis
practices on the development of VRE is consistent with
the observations that one of the first reported outbreaks
of VRE in 1988 occurred in a dialysis unit [16], that in
one study in a single year, from 1995 to 1996, the percent-
age of American hemodialysis facilities reporting treat-
ment of VRE colonized patients jumped from 17 to 21%
[26], and that chronic dialysis patients represented 12 to
22% of cases of VRE in three large, separate hospital-
based studies [26]. Finally, the observation that five of
the seven recently described patients infected with S.
aureus with intermediate susceptibility to vancomycinFig. 1. Survival of vancomycin resistant enterococcal (VRE)-colonized
(solid line) and -noncolonized (dashed line) subjects from time of study were supported on chronic dialysis [9–14] suggests that
entry (P , 0.01). these patients are at a high risk of developing resistant
organisms, including those more virulent than entero-
cocci. In addition, considering that only two of the six
patients in our cohort who were colonized with VRE inthe Treatment of Peritonitis in 1996 changed its recom-
the follow-up 1998 prevalence study had their VRE sta-mendations regarding the empiric treatment of peritoni-
tus previously known to the dialysis staff suggests thattis. Many nephrologists, however, have failed to adopt
the effective surveillance of VRE carriage may requirethese recommendations. In part, this is because of limited
formal regular screening programs, as are routinely con-alternatives in the treatment of methicillin-resistant Staph-
ducted in other high-risk areas such as in intensive careylococcus aureus (MRSA) infections and in part because
units [4].much of the literature to date regarding VRE coloniza-
We demonstrate a clinically and statistically significanttion has been based on patients hospitalized in intensive
independent association between outpatient vancomycincare units or oncology centers [24], and the applicability
use and the development of VRE, a finding in agreementof these studies to the outpatient dialysis setting is uncer-
with several studies examining the determinants of VREtain.
infection in hospitalized patients [21, 24, 27–30]. TheseSeveral studies to date have examined the prevalence
data clearly call into question the long-term safety of the
of VRE in dialysis populations [2, 3, 15, 17, 18] and have
ongoing widespread use of vancomycin in dialysis patients.
been perceived as offering reassurance that the continued They further underscore the need to reduce the incidence
widespread use of vancomycin in these patients has not of dialysis-associated infections, such as by decreasing
been associated with increased rates of developing VRE. the use of hemodialysis catheters [31], and the develop-
More recently, Roghmann et al studied 168 dialysis pa- ment of alternative effective antimicrobials for the treat-
tients and found a VRE prevalence of 9.5% [15]. How- ment of MRSA. In situations in which there is high back-
ever, the cross-sectional nature of these studies leads ground prevalence of MRSA, the initial use of empiric
them to be susceptible to incidence–prevalence bias [25]. vancomycin therapy for suspected infections may be war-
That is, if VRE infection is associated with decreased ranted. However, confirmation of a methicillin-suscepti-
survival, then a high incidence rate will not necessarily ble organism should prompt the rapid conversion to an
result in a high prevalence rate. Thus, cross-sectional alternative antimicrobial regimen. In hemodialysis, cefa-
study designs offer little actual reassurance regarding the zolin when administered postdialysis has been shown to
effect of dialysis-associated antibiotic practices on the maintain therapeutic levels for up to 72 hours and thus
risk of developing VRE. avoid the need for supplemental dosing between dialysis
This high incidence rate for developing VRE raises sessions [32]. The efficacy of cefazolin in peritoneal dial-
the possibility that practices within dialysis units may be ysis patients is, however, less clear [1, 2, 33].
a major driving force in the development and spread of Several important limitations exist regarding our cur-
VRE, especially given the relatively better survival of rent study. Twenty-one percent of our original study
dialysis patients as compared with many intensive care cohort was excluded because a follow-up VRE surveil-
unit patients. Our study confirms the significant contribu- lance culture was not available. The ascertainment of
tion of outpatient vancomycin use in the development VRE status during the study was not uniform, being
dependent on screening performed during hospitaliza-of this high incidence rate. Other factors, including infec-
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